Article
Clinical impact of ABL1 kinase domain mutations and IKZF1 deletion in adults under age 60 with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB (Alliance) 10001 and 9665.
Leukemia & lymphoma - 1 Oct 2016
DeBoer Rebecca, Koval Gregory, Mulkey Flora, Wetzler Meir, Devine Steven, Marcucci Guido, Stone Richard M, Larson Richard A, Bloomfield Clara D, Geyer Susan, Mullighan Charles G, Stock Wendy
Abstract excerpt
Recent studies have identified oncogenic lesions in Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) and ABL1 kinase mutations that confer resistance to tyrosine kinase inhibitors. We sought to determine the prevalence and clinical impact of these lesions in patients on CALGB 10001, a previously reported Phase II study of imatinib, chemotherapy, and hematopoietic cell transplant in adult...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.